Clinical Trials Browser

UNKNOWN × tislelizumab × Clear all

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Phase 2 Unknown

Small Cell Lung Carcinoma